AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38950376
Drug: Treatment based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment based on voiding diaries (dDAVP for nocturnal polyuria with normal MVV; enuresis alarm for reduced MVV and no nocturnal polyuria)
Trial: 38950376
Drug: Randomly allocated
RxNorm normalized name: Alloxate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomly allocated treatment (dDAVP or alarm)
Trial: 38950925
Drug: Niraparib first-line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib first-line maintenance therapy
Trial: 38950931
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia (21 mL of 2% lidocaine and 50 μg fentanyl)
Trial: 38950991
Drug: Full/near-full optical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full/near-full optical treatment requiring wear for at least half their waking hours for 24 weeks.
Trial: 38950991
Drug: Full/near-full optical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full/near-full optical treatment
Trial: 38950995
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin type A (BoNT-A) treatment at different timings
Trial: 38950995
Drug: Rehabilitation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rehabilitation without BoNT-A treatment
Trial: 38950997
Drug: Standard inactivated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard inactivated quadrivalent influenza vaccine
Trial: 38951012
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBM) applied to bilateral knees and lumbar paraspinal points.
Trial: 38951699
Drug: Early integration
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early integration of specialised palliative care (SPC) alongside tumour-specific palliative treatment
Trial: 38951699
Drug: Tumour-specific treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumour-specific treatment alone (Control)
Trial: 38951777
Drug: SM-ART intervention
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SM-ART intervention (six weekly sessions of 60 to 90 minutes)
Trial: 38951902
Drug: CBD oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD oral solution
Trial: 38952209
Drug: Benzodiazepine discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepine discontinuation programme
Trial: 38952554
Drug: Regorafenib (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regorafenib (oral, maximum daily dose of 160 mg for weeks 1-3 of each 4-week cycle)
Trial: 38952672
Drug: Short-course oxaliplatin-based
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Short-course oxaliplatin-based chemotherapy alternating with immune checkpoint blockade (ICB)
Trial: 38952884
Drug: Betamethasone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone (2 doses of 12mg intramuscular)
Trial: 38952884
Drug: Dexamethasone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (2 doses of 12mg intramuscular)
Trial: 38953034
Drug: Icanbelimod 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icanbelimod 0.5 mg
Trial: 38953034
Drug: Icanbelimod (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icanbelimod (various doses)
Trial: 38953542
Drug: Higher adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Higher adalimumab induction dose
Trial: 38953600
Drug: Standard adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard adalimumab dosing regimen
Trial: 38953934
Drug: High FDG
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High FDG Ki group (n=8, Ki > 2.779 ml/min/100 g)
Trial: 38953934
Drug: Low FDG
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low FDG Ki group (n=7, Ki ≤ 2.779 ml/min/100 g)
Trial: 38953936
Drug: Video-based cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video-based cervical stabilization exercises, performed three times a week for six weeks in addition to routine medication.
Trial: 38953936
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group continued routine medication only.
Trial: 38954226
Drug: Brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 210 mg SC at baseline, weeks 1 and 2, and every 2 weeks thereafter until week 16
Trial: 38954226
Drug: Brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 210 mg SC
Trial: 39399879
Drug: TV-46000 once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TV-46000 once monthly (q1m)
Trial: 38954475
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy (3 sessions over 10 weeks)
Trial: 38954680
Drug: Relugolix combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relugolix combination therapy (Myfembree®) after surgical myomectomy
Trial: 38954692
Drug: Probiotic capsule
RxNorm normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic capsule (Lactobacillus salivarius WB21, 6.7 x 108 CFU, xylitol 280mg, 3 times a day for 14 days)
Trial: 38954782
Drug: TK216 administered
RxNorm normalized name: TK216
DrugBank: TK216 (DB17414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TK216 administered as a 14-day continuous infusion
Trial: 38954834
Drug: Genetic deletion
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic deletion of JAM-C (Junctional Adhesion Molecule-C) in leukemic stem cells (LSCs)
Trial: 38954874
Drug: Esketamine nasal
RxNorm normalized name: esketamine Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine nasal spray (NS)
Trial: 38954899
Drug: nab-paclitaxel, gemcitabine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel, gemcitabine, and oxaliplatin (first-line treatment)
Trial: 38954929
Drug: MI-Walk intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MI-Walk intervention (motivational enhancement therapy with 3 counseling sessions, Fitbit Charge 2, exercise diaries, telephone follow-up, motivational emails, optional walking groups)
Trial: 38955178
Drug: Oral terameprocol
RxNorm normalized name: Terameprocol
DrugBank: Terameprocol (DB12226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terameprocol at 1,200 mg/day (n=3)
Trial: 38955178
Drug: Oral terameprocol
RxNorm normalized name: Terameprocol
DrugBank: Terameprocol (DB12226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terameprocol at 2,400 mg/day (n=6)
Trial: 38955178
Drug: Oral terameprocol
RxNorm normalized name: Terameprocol
DrugBank: Terameprocol (DB12226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terameprocol at 3,600 mg/day (n=3)
Trial: 38955178
Drug: Oral terameprocol
RxNorm normalized name: Terameprocol
DrugBank: Terameprocol (DB12226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terameprocol at 6,000 mg/day (n=2)
Trial: 38955178
Drug: Oral terameprocol
RxNorm normalized name: Terameprocol
DrugBank: Terameprocol (DB12226)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terameprocol at 6,000 mg/day in fed state (n=4)
Trial: 38955368
Drug: Plasma solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma solution
Trial: 38955554
Drug: High Troponin
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Troponin I (TnI > 6 ng/L)
Trial: 38955554
Drug: High C-reactive
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High C-reactive protein (CRP > 2 mg/L)
Trial: 38956594
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg microcrystalline cellulose (MCC) placebo
Trial: 38956609
Drug: Mail-order pharmacy
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mail-order pharmacy dispensing for medication abortion
Trial: 38956676
Drug: Less-invasive surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less-invasive surfactant administration (LISA)
Trial: 38956809
Drug: Vincristine exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine exposure with a 20% dose increase for low exposure
Trial: 38956809
Drug: Vincristine exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine exposure without dose increase
Trial: 38957201
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 as an adjuvant therapy to letrozole
Trial: 38957349
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT) with 3 sessions at 2000 impulses, 2.2 Bars pressure, 8 Hz frequency, with a 2-week interval between sessions (Experimental Group A)
Trial: 38957349
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (rESWT) with 3 sessions at 2000 impulses, 2.2 Bars pressure, 8 Hz frequency, with a 4-week interval between sessions (Experimental Group B)
Trial: 38958195
Drug: Triptorelin 11.25
RxNorm normalized name: triptorelin 11.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin 11.25 mg at baseline (≤ 8 weeks after RP) and at 3 and 6 months
Trial: 38958479
Drug: Eltrombopag monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag monotherapy
Trial: 38958845
Drug: New line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New line of therapy following osimertinib and PBC
Trial: 38958845
Drug: New line
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New line of therapy following osimertinib and PBC (matched subset)
Trial: 38958978
Drug: Web-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cognitive behavioral self-help intervention (12 weekly modules)
Trial: 38958989
Drug: Lerodalcibep, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lerodalcibep, 300 mg, subcutaneous injection, monthly for 52 weeks
Trial: 38959264
Drug: Increased water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased water supply by 5 L/user/day
Trial: 38959480
Drug: Tisotumab vedotin
RxNorm normalized name: Tisotumab vedotin
DrugBank: Tisotumab vedotin (DB16732)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tisotumab vedotin (2.0 mg/kg every 3 weeks)
Trial: 38959480
Drug: Chemotherapy (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator's choice: topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
Trial: 38959779
Drug: Losmapimod (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losmapimod (15 mg twice daily for 52 weeks)
Trial: 38960465
Drug: Arm A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A: Rapid hepatitis C virus (HCV) antibody testing
Trial: 38960465
Drug: Arm B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B: Rapid HCV antibody and rapid RNA testing
Trial: 38960465
Drug: Arm C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm C: Rapid HCV antibody testing and same-day treatment initiation for HCV antibody-positive participants
Trial: 38960495
Drug: Social network
RxNorm normalized name: Safety 1st Social Safety Pack KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Social network intervention (weekly social-health classroom interventions for 9 to 10 months)
Trial: 38960626
Drug: ADHD treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADHD treatment responders
Trial: 38960832
Drug: ivabradine (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine (2.5, 5.0, or 7.5 mg) administered twice daily from the morning of surgery until postoperative day 2.
Trial: 38960832
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily from the morning of surgery until postoperative day 2.
Trial: 38961047
Drug: mAb treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mAb treatment (casirivimab plus imdevimab 1200 mg)
Trial: 38961419
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of biomarkers including I-FABP, Alpha-GST, IL-6, PCT, IMA, D-lactate, D-dimer, SCUBE-1, LBP
Trial: 38961430
Drug: Health literacy
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health literacy and psychoeducational coaching sessions, daily 'Life Hacks', slow-paced breathing exercises, step tracker, low-burden food diary, journaling tool
Trial: 38961439
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy (ST) only with nivolumab plus ipilimumab
Trial: 38961460
Drug: Multimodal therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal therapeutic intervention with additional photobiomodulation therapy (PBMT)
Trial: 38962436
Drug: GOE (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOE (900 mg/day)
Trial: 38962958
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 50) setting step goals and receiving daily feedback
Trial: 38963459
Drug: Abiraterone 1000
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone 1000 mg once daily
Trial: 38963583
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood (AB) injection: 1 ml of autologous venous blood mixed with 2 ml of 2% prilocaine HCl
Trial: 38963583
Drug: Corticosteroid (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (CS) injection: 1 ml of 40 mg methylprednisolone acetate mixed with 2 ml of 2% prilocaine HCl
Trial: 38963583
Drug: Combined injection
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined injection (AB + CS): 1 ml each of autologous venous blood and 40 mg methylprednisolone acetate along with 1 ml of 2% prilocaine HCl
Trial: 38964333
Drug: Low-dose radiotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiotherapy (LDRT) plus immune checkpoint inhibitors (ICI)
Trial: 38964333
Drug: Concurrent thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent thoracic LDRT plus chemoimmunotherapy
Trial: 38964361
Drug: V116 (21-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V116 (21-valent pneumococcal conjugate vaccine)
Trial: 38964420
Drug: Fazirsiran 25
RxNorm normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazirsiran 25 mg
Trial: 38964420
Drug: Fazirsiran 100
RxNorm normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazirsiran 100 mg
Trial: 38964420
Drug: Fazirsiran 200
RxNorm normalized name: Fazirsiran
DrugBank: Fazirsiran (DB17891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fazirsiran 200 mg
Trial: 38964799
Drug: Low-dose, non-contrast-enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose, non-contrast-enhanced thoracic CT scans
Trial: 38965031
Drug: Treat-to-target strategy
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target strategy (LDL-C goal of 50-70 mg/dl)
Trial: 38965462
Drug: Intracavernous injections
RxNorm normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracavernous injections of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs)
Trial: 38965541
Drug: Single-inhaler triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-inhaler triple therapy (SITT)
Trial: 38965541
Drug: Multi-inhaler triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-inhaler triple therapy (MITT)
Trial: 38965611
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 40 mg of furosemide intravenously over 10 minutes after fURS
Trial: 38965611
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 40 mg of furosemide
Trial: 38965611
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment with an alpha-blocker
Trial: 38965612
Drug: Concept-guided, personalised,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concept-guided, personalised, motor-cognitive exergame training (twice per week for 30 to 40 minutes)
Trial: 38966802
Drug: cognitive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cognitive treatment as usual
Trial: 38966851
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg Moxidectin (MOX)
Trial: 38966851
Drug: 150 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 µg/kg Ivermectin (IVM)
Trial: 38967929
Drug: Multispecies probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multispecies probiotic formulation consisting of 8 strains from 5 different genera
Trial: 38968243
Drug: Multimodal physiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal physiotherapy program (supervised exercise with laser-guided feedback and interferential current therapy); 8 treatment sessions (twice per week) over 4 weeks
Trial: 38968520
Drug: Anlotinib maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib maintenance therapy
Trial: 38969374
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.5 mg/kg, max 50 mg) over 40 minutes
Trial: 38969374
Drug: Placebo (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.5 mL/kg normal saline, max 50 mL) over 40 minutes
Trial: 38969378
Drug: Soothing cream
RxNorm normalized name: OATMEAL 1 mg in 1 g TOPICAL CREAM [Skin Soothing Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soothing cream gel (SCG)
Trial: 38969866
Drug: siRNA and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siRNA and small molecule inhibitors
Trial: 38969879
Drug: Metronomic vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic vinorelbine (NVB) monotherapy (n=11)
Trial: 38969919
Drug: Somapacitan 5
RxNorm normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Somapacitan 5 mg/1.5 mL
Trial: 38969919
Drug: Somapacitan 10
RxNorm normalized name: SOMAPACITAN 10 mg in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [SOGROYA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somapacitan 10 mg/1.5 mL
Trial: 38969919
Drug: Somapacitan 5
RxNorm normalized name: Somapacitan
DrugBank: Somapacitan (DB15093)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Somapacitan 5 mg/1.5 mL and Somapacitan 10 mg/1.5 mL
Trial: 38970004
Drug: Digital implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital implant impressions DII with TRIOS 3 Shape intraoral scanner
Trial: 38970256
Drug: Pamiparib 60
RxNorm normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamiparib 60 mg twice daily + Temozolomide (TMZ) 60 mg once daily pulsed (7-day schedule)
Trial: 38970327
Drug: RSVPreF3 co-administered
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVPreF3 co-administered with FLU-D-QIV
Trial: 38970327
Drug: Co-administration of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of RSVPreF3 and FLU-D-QIV
Trial: 38970425
Drug: Timrepigene emparvovec
RxNorm normalized name: Timrepigene emparvovec
DrugBank: Timrepigene emparvovec (DB16018)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timrepigene emparvovec (gene therapy), up to 0.1 mL containing 1 × 10^11 vg/mL, administered bilaterally and sequentially.
Trial: 38970713
Drug: No abdominal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No abdominal drain and no prolonged antibiotic prophylaxis
Trial: 38970713
Drug: Abdominal drain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal drain and prolonged antibiotic prophylaxis